Spring 2004 Volume 5, Issue 10:
Atiprimod: A New Drug Candidate in Early-Stage Development for Myeloma
By Gary S. Jacob, PhD CEO, CSO Callisto Pharmaceuticals
Atiprimod has a very interesting history, providing yet another example of a drug candidate that begins its story as a potential treatment for a wholly different disease indication.
|
Be the first to comment